海正药业-话题@MedSci

#海正药业#

9篇内容 | 612人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1928652, encodeId=ea601928652fe, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业海博麦布片成功纳入2021国家医保目录，开启国创降脂新时代, objectType=article, longId=211809, objectId=f06b2118095d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06b2118095d, replyNumber=0, likeNumber=33, createdTime=2021-07-18, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06b2118095d, moduleTitle=海正药业海博麦布片成功纳入2021国家医保目录，开启国创降脂新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06b2118095d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928649, encodeId=996119286492f, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业与圣兆药物建立战略合作，专注高技术壁垒药品，满足广大患者对高质量药品需求, objectType=article, longId=186516, objectId=adec18651691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adec18651691, replyNumber=0, likeNumber=38, createdTime=2020-09-10, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adec18651691, moduleTitle=海正药业与圣兆药物建立战略合作，专注高技术壁垒药品，满足广大患者对高质量药品需求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adec18651691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928651, encodeId=9ee6192865194, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业回应：法匹拉韦流感适应症已报产，考虑申请新冠肺炎临床试验, objectType=article, longId=187867, objectId=62a518e86745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62a518e86745, replyNumber=0, likeNumber=24, createdTime=2020-08-03, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62a518e86745, moduleTitle=海正药业回应：法匹拉韦流感适应症已报产，考虑申请新冠肺炎临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62a518e86745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928650, encodeId=9d2b1928650c0, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业、瀚晖制药赶赴疫情一线，同心遏制新型肺炎, objectType=article, longId=186691, objectId=7752186691bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7752186691bd, replyNumber=0, likeNumber=37, createdTime=2020-02-01, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7752186691bd, moduleTitle=海正药业、瀚晖制药赶赴疫情一线，同心遏制新型肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7752186691bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928648, encodeId=0c111928648d5, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业两款产品以很低价首次中标联盟地区集采的背后, objectType=article, longId=180932, objectId=218118093211, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=218118093211, replyNumber=0, likeNumber=45, createdTime=2020-06-25, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=218118093211, moduleTitle=海正药业两款产品以很低价首次中标联盟地区集采的背后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=218118093211)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928647, encodeId=36f1192864e33, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=梅斯医访谈|对话海正药业 & 瀚晖制药李琰：在寒冬中，拥抱变化是**的道路, objectType=article, longId=160397, objectId=2d9c16039e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d9c16039e34, replyNumber=0, likeNumber=35, createdTime=2019-06-28, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d9c16039e34, moduleTitle=梅斯医访谈|对话海正药业 & 瀚晖制药李琰：在寒冬中，拥抱变化是**的道路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d9c16039e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928645, encodeId=feed1928645e2, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业总裁林剑秋辞职，仍担任董事职务, objectType=article, longId=158661, objectId=9e94158661c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e94158661c0, replyNumber=0, likeNumber=34, createdTime=2019-04-11, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e94158661c0, moduleTitle=海正药业总裁林剑秋辞职，仍担任董事职务, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e94158661c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928646, encodeId=c232192864619, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=李琰接任海正药业新总裁, objectType=article, longId=158821, objectId=4f4c1588210b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f4c1588210b, replyNumber=0, likeNumber=34, createdTime=2019-11-04, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f4c1588210b, moduleTitle=李琰接任海正药业新总裁, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f4c1588210b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928644, encodeId=fea51928644c1, content=<a href='/topic/show?id=3d146561984' target=_blank style='color:#2F92EE;'>#海正药业#</a>, objectTitle=海正药业1.1类抗肿瘤新药光敏剂HPPH获准进入临床试验阶段, objectType=article, longId=34821, objectId=532034821d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=532034821d3, replyNumber=0, likeNumber=36, createdTime=2014-07-11, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=532034821d3, moduleTitle=海正药业1.1类抗肿瘤新药光敏剂HPPH获准进入临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=532034821d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

海正药业

2020-05-29

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业海博麦布片成功纳入2021国家医保目录，开启国创降脂新时代

2021-07-18

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业与圣兆药物建立战略合作，专注高技术壁垒药品，满足广大患者对高质量药品需求

2020-09-10

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业回应：法匹拉韦流感适应症已报产，考虑申请新冠肺炎临床试验

2020-08-03

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业、瀚晖制药赶赴疫情一线，同心遏制新型肺炎

2020-02-01

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业两款产品以很低价首次中标联盟地区集采的背后

2020-06-25

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

梅斯医访谈|对话海正药业 & 瀚晖制药李琰：在寒冬中，拥抱变化是**的道路

2019-06-28

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业总裁林剑秋辞职，仍担任董事职务

2019-04-11

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

李琰接任海正药业新总裁

2019-11-04

lancelotzzl (审核中...)

前往app查看评论内容

#海正药业#

海正药业1.1类抗肿瘤新药光敏剂HPPH获准进入临床试验阶段

2014-07-11

科室
- - 订阅+
  - 更多科室
工具
服务